com_NN
Shareholder_NN
information_NOMZ
AstraZeneca_NN
2000 2001 2002 2003_CD
2004_CD
Ordinary_NN
Shares_NN
in_PIN
issue_NN
millions_NN
At_PIN
year_NN
end_NN
1,766_CD
1,745_CD
1,719_CD
1,693_CD
1,645_CD
Weighted_VBN
average_NN
for_PIN
year_NN
1,768_CD
1,758_CD
1,733_CD
1,709_CD
1,673_CD
Stock_NN
market_NN
price_NN
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
Highest_NN
pence_NN
3600 3555 3625 2868_CD
2749_CD
Lowest_NN
pence_NN
1926 2880 1799 1820_CD
1863_CD
At_PIN
year_NN
end_NN
pence_NN
3375 3098 2220 2680_CD
1889_CD
Earnings_GER
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
before_IN
exceptional_JJ
items_NN
$_$
1.62_CD
$_$
1.73_CD
$_$
1.84_CD
$_$
1.78_CD
$_$
2.11_CD
Earnings_GER
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
basic_JJ
$_$
1.30_CD
$_$
1.65_CD
$_$
1.64_CD
$_$
1.78_CD
$_$
2.28_CD
Earnings_GER
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
diluted_VBD
$_$
1.30_CD
$_$
1.65_CD
$_$
1.64_CD
$_$
1.78_CD
$_$
2.28_CD
Dividends_NN
$_$
0.70_CD
$_$
0.70_CD
$_$
0.70_CD
$_$
0.795_CD
$_$
0.94_CD
In_CONJ
addition_NULL
,_,
shareholders_NN
received_VBD
a_DT
distribution_NOMZ
of_PIN
shares_NN
in_PIN
Syngenta_NN
AG_NN
as_IN
a_DT
dividend_NN
in_PIN
specie_NN
in_PIN
respect_NN
of_PIN
the_DT
demerger_NN
of_PIN
Zeneca_NN
Agrochemicals_NN
._.
Percentage_NN
analysis_NN
at_PIN
31_CD
December_NN
2004_CD
of_PIN
issued_VBN
share_NN
capital_NN
By_PIN
size_NN
of_PIN
account_NN
2004_CD
No._NN
._.
In_CONJ
addition_NULL
,_,
there_EX
were_VBD
approximately_RB
45,000_CD
holders_NN
of_PIN
American_JJ
Depositary_NN
Receipts_NN
ADRs_NN
representing_VBG [WZPRES]
8.82_CD
%_NN
of_PIN
the_DT
issued_VBN
share_NN
capital_NN
and_CC
161,000_CD
holders_NN
of_PIN
shares_NN
held_VBN [PRIV]
under_IN
the_DT
VPC_NN
Services_NN
Agreement_NOMZ
representing_VBG [WZPRES]
22.63_CD
%_NN
of_PIN
the_DT
issued_VBN
share_NN
capital_NN
._.
The_DT
ADRs_NN
,_,
each_QUAN
of_PIN
which_WDT [PIRE]
is_VPRT [BEMA]
equivalent_PRED
to_PIN
one_CD
Ordinary_NN
Share_NN
,_,
are_VPRT [BYPA]
issued_VBN
by_PIN
JPMorgan_NN
Chase_NN
Bank_NN
._.
Financial_NN
calendar_NN
2005_CD
28_CD
April_NN
2005_CD
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
and_CC
announcement_NOMZ
of_PIN
first_JJ
quarter_NN
2005_CD
results_NN
28_CD
July_NN
2005_CD
Announcement_NOMZ
of_PIN
second_JJ
quarter_NN
and_CC
first_JJ
half_NN
2005_CD
results_NN
27_CD
October_NN
2005_CD
Announcement_NOMZ
of_PIN
third_JJ
quarter_NN
and_CC
nine_CD
months_NN
2005_CD
results_NN
Dividend_NN
payments_NOMZ
The_DT
record_NN
date_NN
for_PIN
the_DT
second_JJ
interim_JJ
dividend_NN
for_PIN
2004_CD
,_,
payable_JJ
on_PIN
21_CD
March_NN
2005_CD
in_PIN
the_DT
UK_NN
,_,
the_DT
US_FPP1
and_PHC
Sweden_NN
,_,
is_VPRT [BEMA]
11_CD
February_NN
2005_CD
._.
Shares_NN
trade_NN
ex-dividend_NN
on_PIN
the_DT
London_NN
and_PHC
Stockholm_NN
Stock_NN
Exchanges_NN
from_PIN
9_CD
February_NN
2005_CD
and_CC
ADRs_NN
trade_NN
ex-dividend_NN
on_PIN
the_DT
New_NN
York_NN
Stock_NN
Exchange_NN
from_PIN
the_DT
same_JJ
date_NN
._.
From_PIN
2005_CD
,_,
dividends_NN
will_PRMD [SPAU]
normally_RB
be_VB [PASS]
paid_VBN
as_IN
follows_VPRT
:_:
First_NN
interim_JJ
:_:
Announced_JJ
end_NN
of_PIN
July_NN
and_CC
paid_VBN
in_PIN
September_NN
._.
Second_JJ
interim_NN
:_:
Announced_JJ
end_NN
of_PIN
January_NN
and_CC
paid_VBN
in_PIN
March_NN
._.
The_DT
record_NN
date_NN
for_PIN
the_DT
first_JJ
interim_JJ
dividend_NN
for_PIN
2005_CD
,_,
payable_JJ
on_PIN
19_CD
September_NN
2005_CD
in_PIN
the_DT
UK_NN
,_,
the_DT
US_FPP1
and_PHC
Sweden_NN
,_,
is_VPRT [BEMA]
12_CD
August_NN
2005_CD
._.
2004_CD
dividend_NN
$_$
pence_NN
SEK_NN
Payment_NOMZ
date_NN
First_NN
interim_JJ
dividend_NN
0.295_CD
16.0_CD
2.200_CD
20_CD
September_NN
2004_CD
Second_JJ
interim_JJ
dividend_NN
0.645_CD
34.3_CD
4.497_CD
21_CD
March_NN
2005_CD
Total_JJ
dividend_NN
0.940_CD
50.3_CD
6.697_CD
Annual_JJ
Review_NN
2004_CD
36_CD
astrazeneca_NN
._.
com_NN
The_DT
contents_NN
of_PIN
this_DEMO
AstraZeneca_NN
Annual_JJ
Shareview_NN
Statements_NOMZ
of_PIN
competitive_JJ
position_NOMZ
AstraZenecas_NN
shareholders_NN
with_PIN
internet_NN
Review_NN
are_VPRT [PASS]
derived_VBN
wholly_RB
and_PHC
exclusively_RB
Except_PIN
as_IN
otherwise_CONJ
stated_VBN [PUBV]
,_,
market_NN
information_NOMZ
access_NN
may_POMD
visit_VB
shareview_NN
._.
co._JJ
uk_NN
and_PHC
register_NN
from_PIN
the_DT
AstraZeneca_NN
Annual_JJ
Report_NN
and_CC
in_PIN
this_DEMO
Annual_JJ
Review_NN
2004_CD
regarding_VBG
the_DT
their_TPP3
details_NN
to_TO
create_VB
a_DT
portfolio_NN
._.
Shareview_NN
is_VPRT [BEMA]
a_DT
Form_NN
20-F_JJ
Information_NOMZ
for_PIN
the_DT
financial_JJ
year_NN
position_NOMZ
of_PIN
our_FPP1
business_NOMZ
or_CC
products_NN
relative_JJ
free_JJ
and_PHC
secure_JJ
on-line_JJ
service_NN
from_PIN
Lloyds_NN
TSB_NN
ended_VBD
31_CD
December_NN
2004_CD
,_,
to_PIN
which_WDT [PIRE]
the_DT
reader_NN
to_PIN
its_PIT
or_CC
their_TPP3
competition_NOMZ
is_VPRT [PASS]
based_VBN
upon_PIN
Registrars_NN
that_TSUB
gives_VPRT
access_NN
to_PIN
shareholdings_GER
is_VPRT [PASS]
referred_VBN
for_PIN
additional_JJ
analytical_JJ
information_NOMZ
._.
published_VBN
statistical_JJ
data_NN
for_PIN
the_DT
12_CD
months_NN
including_VBG [WZPRES]
balance_NN
movements_NOMZ
,_,
indicative_JJ
share_NN
ended_VBN
30_CD
September_NN
2004_CD
,_,
obtained_VBN [PASTP]
from_PIN
IMS_NN
prices_NN
and_PHC
information_NOMZ
about_IN
recent_JJ
dividends_NN
._.
Trade_NN
marks_VPRT
Health_NN
,_,
a_DT
leading_VBG
supplier_NN
of_PIN
statistical_JJ
data_NN
to_PIN
Trade_NN
marks_NN
of_PIN
the_DT
AstraZeneca_NN
group_NN
of_PIN
the_DT
pharmaceutical_JJ
industry_NN
._.
Except_PIN
as_IN
ShareGift_NN
companies_NN
appear_VPRT [SMP]
throughout_PIN
this_DEMO
document_NOMZ
in_PIN
otherwise_CONJ
stated_VBN [PUBV]
,_,
these_DEMO
market_NN
share_NN
and_PHC
AstraZeneca_NN
welcomes_VPRT
and_PHC
values_VPRT
all_QUAN
its_PIT
italics_NN
._.
AstraZeneca_NN
,_,
the_DT
AstraZeneca_NN
logotype_NN
industry_NN
data_NN
from_PIN
IMS_NN
Health_NN
have_VPRT [PEAS]
been_VBN
shareholders_NN
,_,
no_SYNE
matter_NN
how_RB
many_QUAN
or_CC
how_RB
few_QUAN
and_CC
the_DT
AstraZeneca_NN
symbol_NN
are_VPRT [BEMA]
all_QUAN
trade_NN
marks_NN
derived_VBN [WZPAST]
by_PIN
comparing_VBG
our_FPP1
sales_NN
revenue_NN
to_PIN
shares_NN
they_TPP3
own_VPRT
._.
However_CONJ
,_,
shareholders_NN
who_WP [WHOBJ]
of_PIN
the_DT
AstraZeneca_NN
group_NN
of_PIN
companies_NN
._.
competitors_NN
and_CC
total_JJ
market_NN
sales_NN
revenues_NN
have_VPRT
only_DWNT
a_DT
small_JJ
number_NN
of_PIN
shares_NN
whose_WPS [WHOBJ]
for_PIN
that_DEMO
period_NN
._.
value_NN
makes_VPRT
it_PIT
uneconomic_JJ
to_TO
sell_VB
them_TPP3
,_,
either_DT
Use_NN
of_PIN
terms_NN
now_TIME
or_CC
at_PIN
some_QUAN
stage_NN
in_PIN
the_DT
future_NN
,_,
may_POMD
wish_VB
In_PIN
this_DEMO
Annual_JJ
Review_NN
2004_CD
,_,
unless_COND
the_DT
context_NN
Statements_NOMZ
of_PIN
growth_NN
rates_NN
to_TO
consider_VB [PRIV]
donating_VBG
them_TPP3
to_PIN
charity_NOMZ
through_PIN
otherwise_CONJ
requires_VPRT [SUAV]
,_,
AstraZeneca_NN
,_,
the_DT
Group_NN
,_,
Except_PIN
as_IN
otherwise_CONJ
stated_VBN [PUBV]
,_,
growth_NN
rates_NN
in_PIN
this_DEMO
ShareGift_NN
,_,
an_DT
independent_JJ
charity_NOMZ
share_NN
the_DT
Company_NN
,_,
we_FPP1
,_,
us_FPP1
and_CC
our_FPP1
refer_VPRT
to_PIN
Annual_JJ
Review_NN
2004_CD
are_VPRT [PASS]
given_VBN
at_PIN
constant_JJ
donation_NOMZ
scheme_NN
._.
One_CD
feature_NN
of_PIN
the_DT
scheme_NN
is_VPRT
AstraZeneca_NN
PLC_NN
and_CC
its_PIT
consolidated_JJ
entities_NOMZ
._.
that_THVC
there_EX
is_VPRT
no_SYNE
gain_NN
or_CC
loss_NN
for_PIN
capital_NN
gains_NN
tax_NN
purposes_NN
on_PIN
gifts_NN
of_PIN
shares_NN
through_PIN
ShareGift_NN
Cautionary_NN
statement_NOMZ
regarding_VBG [WZPRES]
AstraZeneca_NN
websites_NN
and_CC
it_PIT
may_POMD [SPAU]
now_TIME
also_RB
be_VB [BEMA]
possible_PRED
to_TO
obtain_VB
forward-looking_JJ
statements_NOMZ
Information_NOMZ
on_PIN
our_FPP1
websites_NN
,_,
including_VBG
income_NN
tax_NN
relief_NN
on_PIN
the_DT
donation_NOMZ
._.
Further_JJ
In_PIN
order_NN
to_TO
utilise_VB
the_DT
safe_JJ
harbor_NN
provisions_NN
of_PIN
astrazeneca_NN
._.
com_NN
and_PHC
information_NOMZ
about_IN
ShareGift_NN
can_POMD
be_VB [PASS]
found_VBN [PRIV]
the_DT
US_FPP1
Private_NN
Securities_NOMZ
Litigation_NOMZ
Reform_NN
Act_NN
._.
com_NN
does_VPRT
not_XX0
on_PIN
its_PIT
website_NN
,_,
sharegift_NN
._.
org_NN
,_,
or_CC
by_PIN
contacting_VBG
1995_CD
,_,
we_FPP1
are_VPRT
providing_VBG
the_DT
following_VBG
cautionary_JJ
form_NN
part_NN
of_PIN
this_DEMO
document_NOMZ
._.
ShareGift_NN
on_PIN
020 7337 0501_CD
or_CC
at_PIN
46_CD
Grosvenor_NN
statement_NOMZ
:_:
This_DEMO
Annual_JJ
Review_NN
2004_CD
contains_VPRT
Street_NN
,_,
London_NN
W1K_NN
3HN_NN
._.
More_EMPH
information_NOMZ
certain_JJ
forward-looking_JJ
statements_NOMZ
about_IN
about_IN
the_DT
tax_NN
position_NOMZ
on_PIN
gifts_NN
of_PIN
shares_NN
to_PIN
AstraZeneca_NN
._.
Although_CONC
we_FPP1
believe_VPRT [PRIV] [THATD]
our_FPP1
ShareGift_NN
can_POMD
be_VB [PASS]
obtained_VBN
from_PIN
the_DT
Inland_NN
expectations_NOMZ
are_VPRT [PASS]
based_VBN
on_PIN
reasonable_JJ
Revenue_NN
whose_WPS [WHOBJ]
website_JJ
address_NN
is_VPRT
assumptions_NOMZ
,_,
any_QUAN
forward-looking_JJ
statements_NOMZ
inlandrevenue_NN
._.
The_DT
share_NN
transfer_NN
form_NN
may_POMD
be_VB [BYPA]
influenced_VBN
by_PIN
factors_NN
that_TSUB
could_POMD
cause_VB
needed_VBN
to_TO
make_VB
a_DT
donation_NOMZ
may_POMD
be_VB [PASS]
obtained_VBN
actual_JJ
outcomes_NN
and_PHC
results_NN
to_TO
be_VB [BEMA]
materially_RB
from_PIN
the_DT
AstraZeneca_NN
Registrar_NN
,_,
Lloyds_NN
TSB_NN
different_JJ
from_PIN
those_DEMP
predicted_VBN [PUBV]
._.
We_FPP1
identify_VPRT
the_DT
Registrars_NN
whose_WPS [WHOBJ]
address_NN
can_POMD
be_VB [PASS]
found_VBN [PRIV]
on_PIN
the_DT
forward-looking_JJ
statements_NOMZ
by_PIN
using_VBG
the_DT
words_NN
back_RB
cover_VPRT
of_PIN
this_DEMO
document_NOMZ
._.
ShareGift_NN
is_VPRT
anticipates_VPRT [PRIV]
,_,
believes_VPRT [PRIV]
,_,
expects_VPRT [PRIV]
,_,
intends_VPRT [SUAV]
and_CC
AstraZeneca_NN
PLC_NN
2005_CD
administered_VBN
by_PIN
The_DT
Orr_NN
Mackintosh_NN
similar_JJ
expressions_NN
in_PIN
such_JJ
statements_NOMZ
._.
These_DEMO
Foundation_NOMZ
,_,
registered_VBD
charity_NOMZ
number_NN
forward-looking_JJ
statements_NOMZ
are_VPRT [BEMA]
subject_PRED
to_PIN
1052686_CD
._.
numerous_JJ
risks_NN
and_PHC
uncertainties_NN
._.
Important_JJ
factors_NN
that_TSUB
could_POMD
cause_VB
actual_JJ
results_NN
to_TO
differ_VB
The_DT
Unclaimed_NN
Assets_NN
Register_NN
materially_RB
from_PIN
those_DEMP
contained_VBN
in_PIN
forwardAstraZeneca_NN
supplies_NN
unclaimed_JJ
dividend_NN
data_NN
looking_VBG [WZPRES]
statements_NOMZ
,_,
certain_JJ
of_PIN
which_WDT [PIRE]
are_VPRT
beyond_IN
to_PIN
the_DT
Unclaimed_NN
Assets_NN
Register_NN
UAR_NN
which_WDT [WHOBJ]
our_FPP1
control_NN
,_,
include_VPRT
,_,
among_PIN
other_JJ
things_NN
:_:
the_DT
provides_VPRT
investors_NN
who_WP [WHSUB]
have_VPRT [PEAS]
lost_VBN
track_NN
of_PIN
loss_NN
or_CC
expiration_NOMZ
of_PIN
patents_NN
,_,
marketing_GER
shareholdings_GER
with_PIN
an_DT
opportunity_NOMZ
to_TO
search_VB
exclusivity_NOMZ
or_CC
trade_NN
marks_NN
:_:
exchange_NN
rate_NN
the_DT
UARs_NN
database_NN
of_PIN
unclaimed_JJ
financial_JJ
fluctuations_NOMZ
:_:
the_DT
risk_NN
that_TOBJ
R&D_NN
will_PRMD
not_XX0
yield_VB
new_JJ
assets_NN
on_PIN
payment_NOMZ
of_PIN
a_DT
small_JJ
,_,
fixed_JJ
fee_NN
._.
The_DT
products_NN
that_TSUB
achieve_VPRT
commercial_JJ
success_NN
:_:
the_DT
UAR_NN
donates_VPRT
part_NN
of_PIN
the_DT
search_NN
fee_NN
to_PIN
charity_NOMZ
._.
impact_NN
of_PIN
competition_NOMZ
,_,
price_NN
controls_NN
and_PHC
price_NN
The_DT
UAR_NN
can_POMD
be_VB [PASS]
contacted_VBN
at_PIN
Leconfield_NN
reductions_NOMZ
:_:
taxation_NOMZ
risks_NN
:_:
the_DT
risk_NN
of_PIN
substantial_JJ
House_NN
,_,
Curzon_NN
Street_NN
,_,
London_NN
W1J_NN
5JA_NN
product_NN
liability_NOMZ
claims_NN
:_:
the_DT
impact_NN
of_PIN
any_QUAN
failure_NN
and_CC
at_PIN
uar_NN
._.
by_PIN
third_JJ
parties_NN
to_TO
supply_VB
materials_NN
or_CC
services_NN
:_:
the_DT
risk_NN
of_PIN
delay_NN
to_PIN
new_JJ
product_NN
launches_NN
:_:
the_DT
difficulties_NN
of_PIN
obtaining_VBG
and_PHC
maintaining_VBG [PUBV]
governmental_JJ
approvals_NN
for_PIN
products_NN
:_:
and_ANDC
the_DT
risk_NN
of_PIN
environmental_JJ
liabilities_NOMZ
._.
Designed_VBN [PASTP]
by_PIN
Addison_NN
Corporate_NN
Marketing_GER
Ltd_NN
